Evidence map›Paper›PMID 42504211›Full record

ReviewTherapeutic advances in musculoskeletal disease2026

MCCs in adults with autoimmune and inflammatory rheumatic diseases: evidence to date and future directions.

Namrata Singh, Jerry H Gurwitz, Sarah B Lieber

Abstract readReview
In one paragraph

Review in Therapeutic advances in musculoskeletal disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Namrata SinghDivision of Rheumatology, Department of Medicine, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195, USA.ORCID https://orcid.org/0000-0001-7149-363X
Jerry H GurwitzDivision of Geriatric Medicine, Division of Health Systems Science, UMass Chan Medical School, Worcester, MA, USA.
Sarah B LieberDivision of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, NY, USA.

Funding

Preparing For What Is Next With Aducanumab In Real World SettingsR33AG057806 · NIA · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Christopher Barrett Bowling, Ana Roman Quinones · 2018 to 2026
$9.0M
AGS/AGING Learning, Educating, And, Researching National INitiative in Geriatrics (“LEARNING”) CollaborativeR25AG071488 · NIA · AMERICAN GERIATRICS SOCIETY · PI GURWITZ, JERRY H, LUNDEBJERG, NANCY E. · 2021 to 2023
$915k
Improving shared decision-making around the use of disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancerK23AR079588 · NIAMS · UNIVERSITY OF WASHINGTON · PI Namrata Singh · 2022 to 2026
$821k
Tablet-Based Physical Activity Intervention for Frail and Pre-Frail Older Adults with Systemic Lupus ErythematosusK23AG088502 · NIA · HOSPITAL FOR SPECIAL SURGERY · PI Sarah Beth Lieber · 2024 to 2026
$577k
Physical Activity Behaviors and Readiness for a Digital Health Physical Activity Intervention inOlder Adults with Systemic Lupus ErythematosusR03AG082927 · NIA · HOSPITAL FOR SPECIAL SURGERY · PI LIEBER, SARAH BETH · 2023 to 2024
$362k
Impact of rheumatoid arthritis on survival in older adults with cancerR03AG082857 · NIA · UNIVERSITY OF WASHINGTON · PI SINGH, NAMRATA · 2023 to 2024
$289k
Advancing the Science of Multiple Chronic Conditions in Older AdultsR13AG089934 · NIA · AMERICAN GERIATRICS SOCIETY · PI JERRY H GURWITZ, Nancy E. Lundebjerg · 2024 to 2026
$161k
NIAMS NIH HHS K23 AR079588NIA NIH HHS K23 AG088502NIA NIH HHS R03 AG082857NIA NIH HHS R03 AG082927NIA NIH HHS R13 AG089934NIA NIH HHS R25 AG071488NIA NIH HHS R33 AG057806
6 · The paper itself

Abstract

Multiple chronic conditions (MCCs), also known as multimorbidity, are highly prevalent in adults with autoimmune and inflammatory rheumatic diseases (AIIRDs) and significantly complicate their management. This narrative review summarizes current literature on the epidemiology of MCCs in various AIIRDs, highlighting their association with adverse health outcomes and proposing future directions for care. MCCs are ubiquitous across AIIRDs, often exceeding rates seen in age-matched general populations, with prevalence as high as 86% in rheumatoid arthritis and 81.5% in systemic lupus erythematosus cohorts and notable patterns including cardiopulmonary and mental health disorders frequently observed. This substantial MCC burden is consistently linked to adverse outcomes, including increased all-cause mortality, reduced functional status, diminished health-related quality of life, accelerated disability, higher healthcare utilization, and increased costs, driven by chronic inflammation, lifestyle, and treatment effects. Therefore, rheumatology care must adopt a holistic, person-centered framework that actively recognizes and manages MCCs, leveraging multidisciplinary teams and integrating evidence-based interventions guided by frameworks such as the geriatric 5Ms and 5Ts to advance the science of MCCs in adults with AIIRDs and improve outcomes and optimize health-related quality of life in this complex patient population.

Indexed as

multimorbiditymultiple chronic conditionsrheumatic diseases

Identifiers

PMID42504211
PMCPMC13401637

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.